Tags

Type your tag names separated by a space and hit enter

Chromium nicotinate has no effect on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes.
J Am Coll Nutr 2013; 32(4):243-50JA

Abstract

OBJECTIVE

To investigate the effect of chromium nicotinate supplementation on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes.

MATERIALS AND METHODS

In a double-blind clinical trial, 56 overweight individuals with type 2 diabetes were randomized into 3 groups: placebo (NC0), 50 μg (NC50), and 200 μg (NC200) of chromium as chromium nicotinate. Chromium status, sensitivity to insulin, glycemic control, and lipid profile were assessed at the beginning of the study and 45 days and 90 days after.

RESULTS

In the beginning, most subjects showed low concentrations of serum chromium (71.88%), regular levels of urinary chromium (80.65%), and insulin resistance (73.80%). The serum chromium concentrations did not differ among the groups over time (p = 0.2549). The changes in serum chromium and urine concentrations did not relate to changes in fasting glucose (p > 0.05). At 90 days of intervention, there was no significant difference between groups in fasting glucose, glycosylated hemoglobin, homeostasis model assessment insulin resistance (HOMA-IR), total cholesterol, and low-density lipoprotein (LDL); there was increase in homeostasis model assessment β-cell function (HOMA-β; p = 0.0349) and high-density lipoprotein (HDL; p = 0.0425) in the NC0 group and a reduction of triglycerides in the NC0 (p = 0.0177) and NC50 (p = 0.0336) groups.

CONCLUSION

Supplementation at 50 and 200 μg of chromium as chromium nicotinate did not promote glycemic control, increase insulin sensitivity, or change the lipid profile of subjects with diabetes.

Authors+Show Affiliations

a Graduate Program in Health Sciences.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

24024769

Citation

Guimarães, Marília Mendonça, et al. "Chromium Nicotinate Has No Effect On Insulin Sensitivity, Glycemic Control, and Lipid Profile in Subjects With Type 2 Diabetes." Journal of the American College of Nutrition, vol. 32, no. 4, 2013, pp. 243-50.
Guimarães MM, Martins Silva Carvalho AC, Silva MS. Chromium nicotinate has no effect on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes. J Am Coll Nutr. 2013;32(4):243-50.
Guimarães, M. M., Martins Silva Carvalho, A. C., & Silva, M. S. (2013). Chromium nicotinate has no effect on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes. Journal of the American College of Nutrition, 32(4), pp. 243-50. doi:10.1080/07315724.2013.816598.
Guimarães MM, Martins Silva Carvalho AC, Silva MS. Chromium Nicotinate Has No Effect On Insulin Sensitivity, Glycemic Control, and Lipid Profile in Subjects With Type 2 Diabetes. J Am Coll Nutr. 2013;32(4):243-50. PubMed PMID: 24024769.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chromium nicotinate has no effect on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes. AU - Guimarães,Marília Mendonça, AU - Martins Silva Carvalho,Ana Clara, AU - Silva,Maria Sebastiana, PY - 2013/9/13/entrez PY - 2013/9/13/pubmed PY - 2014/4/11/medline SP - 243 EP - 50 JF - Journal of the American College of Nutrition JO - J Am Coll Nutr VL - 32 IS - 4 N2 - OBJECTIVE: To investigate the effect of chromium nicotinate supplementation on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes. MATERIALS AND METHODS: In a double-blind clinical trial, 56 overweight individuals with type 2 diabetes were randomized into 3 groups: placebo (NC0), 50 μg (NC50), and 200 μg (NC200) of chromium as chromium nicotinate. Chromium status, sensitivity to insulin, glycemic control, and lipid profile were assessed at the beginning of the study and 45 days and 90 days after. RESULTS: In the beginning, most subjects showed low concentrations of serum chromium (71.88%), regular levels of urinary chromium (80.65%), and insulin resistance (73.80%). The serum chromium concentrations did not differ among the groups over time (p = 0.2549). The changes in serum chromium and urine concentrations did not relate to changes in fasting glucose (p > 0.05). At 90 days of intervention, there was no significant difference between groups in fasting glucose, glycosylated hemoglobin, homeostasis model assessment insulin resistance (HOMA-IR), total cholesterol, and low-density lipoprotein (LDL); there was increase in homeostasis model assessment β-cell function (HOMA-β; p = 0.0349) and high-density lipoprotein (HDL; p = 0.0425) in the NC0 group and a reduction of triglycerides in the NC0 (p = 0.0177) and NC50 (p = 0.0336) groups. CONCLUSION: Supplementation at 50 and 200 μg of chromium as chromium nicotinate did not promote glycemic control, increase insulin sensitivity, or change the lipid profile of subjects with diabetes. SN - 1541-1087 UR - https://www.unboundmedicine.com/medline/citation/24024769/Chromium_nicotinate_has_no_effect_on_insulin_sensitivity_glycemic_control_and_lipid_profile_in_subjects_with_type_2_diabetes_ L2 - http://www.tandfonline.com/doi/full/10.1080/07315724.2013.816598 DB - PRIME DP - Unbound Medicine ER -